Sanofi: Tetanus trials

The registry lists 78 Tetanus studies with Sanofi as lead sponsor. 0 are open to participants now and 43 have results posted.

Phase 1 4Phase 2 7Phase 3 42Phase 4 20No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompletedNCT04398706Phase 2Results posted
• Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy SubjectsCompletedNCT02587520Phase 1/2Results posted
• Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years OldCompletedNCT02089347Phase 3Results posted
• Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at BirthCompletedNCT01948193Phase 3Results posted
• Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in ChinaCompletedNCT01933776Phase 1Results posted
• Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in AdolescentsCompletedNCT01689324Phase 1/2Results posted
• Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of AgeCompletedNCT01659996Phase 4Results posted
• Immunogenicity of Adacel® and BOOSTRIX® Vaccines in AdolescentsCompletedNCT01629589Phase 4Results posted
• Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy InfantsCompletedNCT01444781Phase 3Results posted
• Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous DoseCompletedNCT01439165Phase 4Results posted
• Regulatory Post-Marketing Surveillance Study for TETRAXIM™CompletedNCT01437423Phase 4Results posted
• Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of AgeCompletedNCT01346293Phase 3Results posted
• Study of Adacel® Vaccine Administered to Persons 10 Years of AgeCompletedNCT01311557Phase 4Results posted
• A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American InfantsCompletedNCT01177722Phase 3Results posted
• Post Marketing Surveillance for ADACEL™ in South KoreaCompletedNCT01137435Phase 4Results posted
• A Study to Assess the Safety of Adacel® VaccineCompletedNCT01040052Phase 3Results posted
• Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian InfantsCompletedNCT00831753Phase 3Results posted
• Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean InfantsCompletedNCT00831311Phase 2Results posted
• Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™CompletedNCT00802867Phase 4Results posted
• Immunogenicity and Safety of Adacel Polio VaccineCompletedNCT00797511Phase 3Results posted
• Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap VaccineCompletedNCT00777257Phase 4Results posted
• Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™CompletedNCT00772928Phase 3Results posted
• Retrospective Survey of Safety of Fourth Dose Pentacel® in ChildrenCompletedNCT00772369Results posted
• Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous DoseCompletedNCT00712959Phase 4Results posted
• Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™CompletedNCT00654901Phase 3Results posted
• Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured TdCompletedNCT00601835Phase 4Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™CompletedNCT00534833Phase 3Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino InfantsCompletedNCT00514709Phase 3Results posted
• Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of AgeCompletedNCT00467519Phase 3Results posted
• A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and OlderCompletedNCT00457249Phase 4Results posted
• Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy InfantsCompletedNCT00404651Phase 3Results posted
• Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®CompletedNCT00355121Phase 2Results posted
• Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy InfantsCompletedNCT00348881Phase 3Results posted
• Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® VaccineCompletedNCT00347958Phase 4Results posted
• Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio VaccineCompletedNCT00343889Phase 3Results posted
• Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®CompletedNCT00319553Phase 4Results posted
• Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.CompletedNCT00313911Phase 3Results posted
• Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis VaccineCompletedNCT00304265Phase 4Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean InfantsCompletedNCT00303316Phase 3Results posted
• Immunogenicity and Safety of ADACEL™ as Fifth Dose in TaiwanCompletedNCT00258908Phase 3Results posted
• Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®CompletedNCT00258895Phase 3Results posted
• Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ VaccineCompletedNCT00258882Results posted
• Safety and Immune Response of Different Pediatric Combination Vaccines.CompletedNCT00255047Phase 3Results posted
• Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in ThailandCompletedNCT04429295Phase 3
• Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South AfricaCompletedNCT04300192Phase 4
• A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in CanadaCompletedNCT03958799Phase 1
• DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected InfantsCompletedNCT02817451Phase 3
• Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After BirthCompletedNCT02428491Phase 3
• DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese InfantsCompletedNCT02274285Phase 3
• DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed InfantsCompletedNCT02094833Phase 3
• Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated PoliomyelitisCompletedNCT02040636Phase 2
• Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.CompletedNCT01993173Phase 3
• Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa VaccinationCompletedNCT01983540Phase 3
• Post Authorisation Safety Study of Triaxis as a 5th Dose in 4-6 Year Old Spanish ChildrenCompletedNCT01583049
• Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRECompletedNCT01546909Phase 4
• Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in ChinaCompletedNCT01491087Phase 4
• Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or OlderCompletedNCT01287949Phase 3
• Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years OldCompletedNCT01249183Phase 3
• Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.CompletedNCT01214889Phase 3
• Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control VaccineCompletedNCT01105559
• A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy InfantsCompletedNCT01062477Phase 3
• Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of AgeCompletedNCT01031303Phase 4
• Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy AdultsCompletedNCT00928785Phase 3
• Surveillance Program to Determine Product Specific Rates of Invasive Hib DiseaseCompletedNCT00855855
• Database Surveillance Safety Study of PENTACEL® VaccineCompletedNCT00804284
• Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended VaccineCompletedNCT00662870Phase 3
• Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of AgeCompletedNCT00524732
• Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 MonthsCompletedNCT00453570Phase 3
• REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old ChildrenCompletedNCT00447525Phase 3
• Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®CompletedNCT00362427Phase 2
• Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®CompletedNCT00355654Phase 3
• Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and ToddlersCompletedNCT00343421Phase 3
• Immunogenicity and Safety of Tetraxim Versus Local DTP + IPVCompletedNCT00319852Phase 3
• Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in InfantsCompletedNCT00287092Phase 3
• Immunogenicity and Safety of Pentaxim™ in an Indian PopulationCompletedNCT00259337Phase 3
• Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in ThailandCompletedNCT00255021Phase 4
• Immunogenicity and Safety of Pentaxim in South African InfantsCompletedNCT00254969Phase 3
• Assessment of the Immunogenicity and Safety of PENTAXIM™ in PhilippinesCompletedNCT00254917Phase 4